8-K: Leap Therapeutics Reports Positive Phase 2 Data and First Quarter 2025 Financial Results Amidst Strategic Restructuring

Leap Therapeutics announced positive data from its Phase 2 DeFianCe study and its Q1 2025 financial results, alongside a strategic restructuring involving a workforce reduction.

Summary

• Leap Therapeutics reported financial results for the first quarter of 2025 and provided updates on its clinical and preclinical programs.
• The company highlighted positive data from the Phase 2 DeFianCe study of sirexatamab in second-line colorectal cancer (CRC) patients, showing significantly higher overall response rate (ORR) and longer progression-free survival (PFS) in specific subgroups.
• Leap presented preclinical data for FL-501, a novel GDF-15 neutralizing antibody, at the AACR 2025 Annual Meeting.
• A strategic restructuring was implemented to prioritize the clinical development of sirexatamab in CRC and advance FL-501 in preclinical development, resulting in an approximately 50% workforce reduction.
• The net loss for the first quarter of 2025 was $15.4 million, compared to $13.8 million for the same period in 2024, primarily due to increased research and development expenses.
• Cash and cash equivalents totaled $32.7 million at March 31, 2025.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Positive clinical data is offset by financial losses and a significant workforce reduction. The strategic restructuring could be beneficial in the long term, but it introduces short-term uncertainty.

Positives

• Positive data from the Phase 2 DeFianCe study suggests potential for sirexatamab in treating second-line CRC patients.
• FL-501 shows promise as a potential treatment for cachexia, with favorable preclinical data.
• The strategic restructuring aims to focus resources on the most promising programs, potentially increasing efficiency and shareholder value.
• The company is exploring business development opportunities to further the development of sirexatamab.
• The company hosted a virtual KOL event to discuss the benefits of the DeFianCe study.

Negatives

• The company experienced a net loss of $15.4 million in Q1 2025, higher than the $13.8 million loss in Q1 2024.
• The company reduced its workforce by approximately 50% as part of a strategic restructuring, which may impact morale and productivity.
• Cash and cash equivalents decreased from $47.249 million at December 31, 2024, to $32.713 million at March 31, 2025.

Risks

• The success of sirexatamab in future clinical trials is not guaranteed.
• Regulatory approval for sirexatamab and FL-501 is not assured.
• The company's financial position is constrained, with limited cash reserves.
• The strategic restructuring may not achieve the desired results.
• The company's ability to regain compliance with the Nasdaq Capital Market listing criteria is uncertain.
• The company's ability to remain a going concern is uncertain.

Future Outlook

The company anticipates upcoming data updates from the DeFianCe study this quarter and is focused on advancing sirexatamab in CRC and FL-501 preclinically. The company is also exploring business development opportunities to further the development of sirexatamab.

Management Comments

• Douglas E. Onsi, President and Chief Executive Officer of Leap, stated that sirexatamab continued to demonstrate encouraging efficacy and expressed optimism about the maturing dataset in the full population.
• Douglas E. Onsi also stated that the company focused its resources to position Leap to advance sirexatamab in CRC and FL-501 preclinically in order to provide the greatest value for shareholders.

Industry Context

Leap Therapeutics is operating in the competitive biotechnology industry, focusing on targeted and immuno-oncology therapeutics. The company's focus on CRC and cachexia aligns with significant unmet needs in cancer treatment. Competitors in the CRC space include companies developing novel therapies targeting similar pathways, while companies like visugromab and ponsegromab are developing treatments for cachexia.

Comparison to Industry Standards

• The reported ORR and PFS improvements in the DeFianCe study need to be compared to existing second-line CRC treatments to assess the competitive advantage of sirexatamab.
• The preclinical data for FL-501 should be benchmarked against clinical-stage antibodies like visugromab and ponsegromab to determine its potential as a best-in-class molecule.
• The company's cash runway of $32.7 million should be compared to the average cash burn rate of similar-sized biotech companies to assess its financial stability.

Stakeholder Impact

• Shareholders may be impacted by the strategic restructuring and the company's financial performance.
• Employees have been impacted by the workforce reduction.
• Patients with CRC may benefit from the potential development of sirexatamab.
• The company's suppliers and creditors may be affected by the restructuring and changes in spending.

Next Steps

• The company expects updated data from the DeFianCe study this quarter.
• Leap plans to initiate a registrational Phase 3 clinical trial to evaluate sirexatamab plus bevacizumab and chemotherapy in second-line MSS CRC patients with high DKK1 levels or in patients who have not received prior anti-VEGF therapy.
• The company will continue to advance FL-501 in preclinical development.
• Leap will explore business development opportunities to further the development of sirexatamab.

Key Dates

Keywords

Leap Therapeutics, Sirexatamab, DKN-01, FL-501, Colorectal Cancer, CRC, GDF-15, Cachexia, Clinical Trial, Phase 2, DeFianCe Study, Financial Results, Restructuring, Biotechnology, Oncology